{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06455280",
            "orgStudyIdInfo": {
                "id": "AAAU7303"
            },
            "organization": {
                "fullName": "Columbia University",
                "class": "OTHER"
            },
            "briefTitle": "SIPLIZUMAB in AILD and LT",
            "officialTitle": "A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)",
            "acronym": "SET-SAIL",
            "therapeuticArea": [
                "Other",
                "Gastroenterology"
            ],
            "study": "siplizumab-in-aild-and-lt"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-07",
            "studyFirstSubmitQcDate": "2024-06-07",
            "studyFirstPostDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Elizabeth C. Verna",
                "investigatorTitle": "Frank Cardile Associate Professor of Medicine",
                "investigatorAffiliation": "Columbia University"
            },
            "leadSponsor": {
                "name": "Elizabeth C. Verna",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "ITB-Med LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT.\n\nUp to eight (8) subjects will receive siplizumab 0.6 mg/kg/dose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses.\n\nAll subjects will be followed in the study for 12 months post-LT.",
            "detailedDescription": "The purpose of this study is to evaluate the safety of siplizumab when used as induction immunosuppression in patients with PSC or AIH undergoing liver transplantation. Induction immunosuppression drugs are very potent anti-rejection drugs that are given immediately after transplantation to prevent rejection. Siplizumab is investigational, meaning it has not yet been approved for market use for this disease condition by the United States Food and Drug Administration (FDA).\n\nAdult patients (18 years of age and older) listed for LT with the specific AILD diagnoses of PSC or AIH\n\nAll subjects will receive 0.6 mg/kg/dose intravenously on the day of transplant (Day 0) intraoperatively and on post-transplant Day 4.\n\nParticipation in this study will last approximately 15 months (\\~ 3 months on the LT waitlist, up to 12 months participation post-LT)"
        },
        "conditionsModule": {
            "conditions": [
                "Autoimmune Liver Disease",
                "Liver Transplant Disorder",
                "Autoimmune Hepatitis",
                "Primary Sclerosing Cholangitis",
                "End Stage Liver DIsease",
                "Cirrhosis, Liver"
            ],
            "keywords": [
                "Autoimmune Liver Disease",
                "Liver Transplant Disorder",
                "Autoimmune Hepatitis",
                "Primary Sclerosing Cholangitis",
                "End Stage Liver DIsease",
                "Cirrhosis, Liver"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Open-Label Study",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 8,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Open Label",
                    "type": "EXPERIMENTAL",
                    "description": "subjects will receive 0.6 mg/kg/dose intravenously on the day of transplant (Day 0) intraoperatively and on post-transplant Day 4.",
                    "interventionNames": [
                        "Drug: Siplizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Siplizumab",
                    "description": "Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.",
                    "armGroupLabels": [
                        "Open Label"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Serious infection in the first month post-transplant,",
                    "description": "viral, bacterial or fungal infection that leads to readmission, prolonged hospitalization, reoperation, intensive care unit admission, graft loss or death.",
                    "timeFrame": "1 Month post-transplant"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Incidence of immune-mediated liver injury",
                    "description": "biopsy proven acute rejection \\[BPAR\\], or recurrent AILD",
                    "timeFrame": "12 month Post-transplant"
                },
                {
                    "measure": "Incidence of graft loss or death",
                    "description": "Loss of liver allograft or incidence of mortality",
                    "timeFrame": "12 month Post-transplant"
                },
                {
                    "measure": "Incidence of BPAR",
                    "description": "biopsy proven acute rejection within 12 Month post-transplant",
                    "timeFrame": "12 month Post-transplant"
                },
                {
                    "measure": "Incidence of treated BPAR",
                    "description": "biopsy proven acute rejection that requires treatment within 12 Month post-transplant",
                    "timeFrame": "12 month Post-transplant"
                },
                {
                    "measure": "Incidence of refractory BPAR",
                    "description": "biopsy proven acute rejection within 12 Month post-transplant that is not responsive to treatment",
                    "timeFrame": "12 month Post-transplant"
                },
                {
                    "measure": "Incidence of development of donor specific antibodies (DSA)",
                    "description": "Donor specific antibodies within 12 Month Post-transplant",
                    "timeFrame": "12 month Post-transplant"
                },
                {
                    "measure": "Incidence of recurrent AILD",
                    "description": "based upon histology for autoimmune hepatitis \\[AIH\\] and histology and/or imaging for primary sclerosing cholangitis \\[PSC\\]",
                    "timeFrame": "12 month Post-transplant"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Peak plasma concentration (Cmax) after single dose of siplizumab",
                    "description": "Cmax after single dose",
                    "timeFrame": "12 hours Post-treatment"
                },
                {
                    "measure": "The area under the curve (AUC) from time zero to the last measurable plasma concentration sampling time.",
                    "description": "AUC based on plasma concentrations over 84 days post-treatment",
                    "timeFrame": "84 Days Post-transplant"
                },
                {
                    "measure": "Descriptive summary statistics by dosing level and visit/sampling time point",
                    "description": "the frequency of siplizumab concentrations below the lower-limit of quantification (LLOQ)",
                    "timeFrame": "12 month Post-transplant"
                },
                {
                    "measure": "Summary statistics of PK of Siplizumab",
                    "description": "mean, standard deviation (SD), coefficient of variation (CV), median, minimum and maximum of siplizumab concentrations.",
                    "timeFrame": "12 month Post-transplant"
                },
                {
                    "measure": "Change in peripheral immunophenotype",
                    "description": "Measurement of subsets of T-, B- and NK-cells",
                    "timeFrame": "12 month Post treatment"
                },
                {
                    "measure": "CD2 receptor occupancy by dose level and subject",
                    "description": "Measurement of CD2 receptor occupancy",
                    "timeFrame": "12 month Post-transplant"
                },
                {
                    "measure": "Dynamics of T-cell subset recovery in the blood and allograft liver",
                    "description": "Measurement of T-cell subset in the blood and allograft liver",
                    "timeFrame": "12 month Post-transplant"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age \u2265 18 years old\n3. Clinical diagnosis of AIH and/or PSC\n4. Listed for liver transplantation\n5. EBV seropositive within 12 months of screening\n\nExclusion Criteria:\n\n1. Presence or history of significant liver disease other than AIH or PSC, including viral hepatitis, alcohol-related liver disease and biopsy-proven non-alcoholic steatohepatitis\n2. Prior transplant\n3. Listed for multiorgan transplant\n4. Acute liver failure\n5. Known malignancy, including cholangiocarcinoma and hepatocellular carcinoma\n6. Other investigational products in the last 30 days or 5 half lives\n7. Pregnant/lactating or unwilling to use contraception\n8. Leukopenia (WBC less than 2,000/mm3\n9. Absolute lymphocyte count \\< 200/mm3\n10. Sero-positive for HIV-1\n11. HCV antibody or RNA positive (within 6 months of screening)\n12. HBsAg, HBV DNA or HBcAb positive (within 6 months of screening)\n13. Alcohol use exceeding 30g/day for men or 20g/day for women, and/or known PETH level \\>80 in the 3 months prior to LT\n14. Untreated latent TB infection as detected by QuantiFERON Gold Plus IGRA (or current standard interferon gamma release assay for TB)\n15. Receipt of any live-attenuated vaccine within 2 months of transplant.\n\nADDITIONAL exclusion criteria to be reviewed at the TIME OF TRANSPLANT\n\n1. Renal failure with dialysis or with eGFR \\< 30 at the time of LT\n2. MELD-Na score \\>30\n3. Donor features of Donation after Cardiac Death (DCD), HCV Ab or NAT+, HBcAb or HBsAg+, or ABO incompatible organ",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Theresa Lukose, PharmD",
                    "role": "CONTACT",
                    "phone": "212-305-3839",
                    "email": "tt2103@cumc.columbia.edu"
                },
                {
                    "name": "Amanda Alonso, MHA",
                    "role": "CONTACT",
                    "phone": "212-342-0261",
                    "email": "aa2974@cumc.columbia.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Elizabeth Verna, MD",
                    "affiliation": "Columbia University Irving Medical Center/ New York Presbyterian Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Columbia University Irving Medical Center/NewYork-Presbyterian Hospital",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Theresa Lukose, PharmD",
                            "role": "CONTACT",
                            "phone": "212-305-3839",
                            "email": "tt2103@cumc.columbia.edu"
                        },
                        {
                            "name": "Elizabeth Verna, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Kwong, A., et al., OPTN/SRTR 2018 Annual Data Report: Liver. Am J Transplant, 2020. 20 Suppl s1: p. 193- 299.",
                    "url": "https://pubmed.ncbi.nlm.nih.gov/31898413/"
                },
                {
                    "label": "Qian, J., et al., Studies on the induction of tolerance to alloantigens. I. The abrogation of potentials for delayed-type-hypersensitivity response to alloantigens by portal venous inoculation with allogeneic cells. J Immunol, 1985. 134(6): p. 3656-61.",
                    "url": "https://pubmed.ncbi.nlm.nih.gov/2580893/"
                },
                {
                    "label": "Gugenheim, J., et al., Delayed rejection of heart allografts in hypersensitized rats by extracorporeal donorspecific liver hemoperfusion. Transplantation, 1986. 41(3): p. 398-400.",
                    "url": "https://pubmed.ncbi.nlm.nih.gov/3513399/"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006505",
                    "term": "Hepatitis"
                },
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000008103",
                    "term": "Liver Cirrhosis"
                },
                {
                    "id": "D000002761",
                    "term": "Cholangitis"
                },
                {
                    "id": "D000015209",
                    "term": "Cholangitis, Sclerosing"
                },
                {
                    "id": "D000058625",
                    "term": "End Stage Liver Disease"
                },
                {
                    "id": "D000019693",
                    "term": "Hepatitis, Autoimmune"
                },
                {
                    "id": "D000005355",
                    "term": "Fibrosis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000001649",
                    "term": "Bile Duct Diseases"
                },
                {
                    "id": "D000001660",
                    "term": "Biliary Tract Diseases"
                },
                {
                    "id": "D000017093",
                    "term": "Liver Failure"
                },
                {
                    "id": "D000048550",
                    "term": "Hepatic Insufficiency"
                },
                {
                    "id": "D000006521",
                    "term": "Hepatitis, Chronic"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "asFound": "Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11103",
                    "name": "Liver Cirrhosis",
                    "asFound": "Cirrhosis, Liver",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9592",
                    "name": "Hepatitis A",
                    "relevance": "LOW"
                },
                {
                    "id": "M9591",
                    "name": "Hepatitis",
                    "asFound": "Hepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6002",
                    "name": "Cholangitis",
                    "asFound": "Cholangitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17914",
                    "name": "Cholangitis, Sclerosing",
                    "asFound": "Primary Sclerosing Cholangitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21608",
                    "name": "Hepatitis, Autoimmune",
                    "asFound": "Autoimmune Hepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M29168",
                    "name": "End Stage Liver Disease",
                    "asFound": "End Stage Liver Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8485",
                    "name": "Fibrosis",
                    "asFound": "Cirrhosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4935",
                    "name": "Bile Duct Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4946",
                    "name": "Biliary Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19415",
                    "name": "Liver Failure",
                    "relevance": "LOW"
                },
                {
                    "id": "M25970",
                    "name": "Hepatic Insufficiency",
                    "relevance": "LOW"
                },
                {
                    "id": "M9607",
                    "name": "Hepatitis, Chronic",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4712",
                    "name": "Primary Sclerosing Cholangitis",
                    "asFound": "Primary Sclerosing Cholangitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T558",
                    "name": "Autoimmune Hepatitis",
                    "asFound": "Autoimmune Hepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                }
            ]
        }
    },
    "hasResults": false
}